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ABSTRACT
Down syndrome (DS) is the most common genetic form of cognitive disability and is
caused by trisomy of chromosome 21. Within chromosome 21 is the gene, amyloid
precursor protein (APP). Proteolysis of APP into toxic and aggregate-prone, betaamyloid fragments underlies the pathophysiology of Alzheimer’s disease (AD).
Individuals with DS develop the neuropathology that can be diagnosed as AD;

however, the role of APP overexpression in this comorbidity is presently unclear.

Here, we elucidated the mechanism of cell death induced by overexpression of wild
type APP. Chinese hamster ovary cells transfected with a DsRed-APP fusion

construct displayed caspase-3 activation and nuclear fragmentation indicative of

apoptosis. APP-induced apoptosis was blocked by a pan-caspase inhibitor, (BOC),

glutathione (GSH), or co-expression of Bcl-2. APP caused depletion of mitochondrial

GSH, induced opening of the permeability transition pore, and triggered cytochrome
c release. Each of these events was inhibited by GSH but was unaffected by BOC

indicating that they were oxidative stress-dependent and upstream of caspases. We
conclude that APP overexpression is sufficient to cause mitochondrial oxidative

stress and intrinsic apoptosis. We are currently examining if a similar cell death
pathway is induced by APP in neuronal cells. Our data are consistent with an

increased expression of APP being a likely contributor to neuron death in DS. Thus,
ii

decreasing APP-induced oxidative stress and apoptosis may be beneficial in
reducing the comorbid phenotype of DS patients afflicted with AD.
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1.1 Down Syndrome

CHAPTER ONE: INTRODUCTION

Down syndrome (DS) was first described by a British physician, John L. H.

Down in 1866, it was first characterized by the mental retardation and unique

facial appearances that Individuals with down syndrome develop. DS is caused
by a partial or full triplication of chromosome 21 (HSA21), the smallest of the

human chromosomes. DS occurs in approximately one in every 800 births [1].
When there is a chromosomal triplication in utero in the first and second

trimester, DS occurs at a rate of 75% and 50% respectively; unfortunately these
trisomic individuals are lost before they make it full term [2]. The hallmarks of

DS include intellectual disability, hypotonia, and an abnormally shaped cranium.
Individuals with down syndrome present an array of health problems including

atrial and ventricular septal defects, dementia (Alzheimer’s), cataracts, leukemia,
sleep apnea and hypothyroidism, to name a few. Interestingly, Individuals with
down syndrome present a decreased risk of breast and lung cancers as well as

atherosclerosis [3]. DS arises from a maternal non-disjunction event in meiosis
I, which can lead to the triplication of HSA21. Older mothers have an increased
risk of producing a child with DS. Full triplication of HSA21 encompasses

roughly 95% of DS cases, whereas partial triplication and mosaicism of HSA21
comprise the minority of DS cases [4, 5]. The triplication of HSA21 has caused

some genes on that chromosome to be overexpressed by ~50% in many tissues
1

[5]. Currently it is not known how this relatively small increase in transcript
levels results in the common features of DS.

Individuals with DS display features of premature aging of which an AD

type dementia appears to be a prominent characteristic [6]. These individuals

experience increased seizures and by their mid-40s develop the neuropathology
of AD characterized by β-amyloid (Aβ) plaques, neurofibrillary tangles

consisting of hyperphosphorylated Tau, and basal forebrain cholinergic neuron

degeneration [7]. The AD pathology that Individuals with DS develop also leads
to a loss of neurons in the hippocampus and cortex, cell populations associated

with memory and learning, and information processing respectively. The loss of
neurons in these areas is thought to play a significant role in the cognitive
disability that individuals with down syndrome present.

In regards to the relationship between the overexpression of specific

genes on HSA21 and the pathology of DS there are two leading hypotheses. The
first is the gene dosage hypothesis, which states that due to the presence of an

extra HSA21 there is a correspondingly 50% increase in the expression of genes

on this chromosome that directly or indirectly alter the timing, pattern or extent
of neuronal development [8]. The second hypothesis is the genetic homeostasis
hypothesis which states it is the expression of extra genes, regardless of their
identity or function, that leads to phenotypic alterations [9]. These two

hypotheses aim to explain the abnormal development that is observed in DS
individuals. Overexpression of certain genes may play a positive role in
2

mitigating the pathological consequences of DS such as super oxide dismutase 1
(SOD1), which converts free radicals to less damaging species, or glycinamine

ribonucletide synthase-aminoimidazole ribonucleotide synthase-glycinamide
formyl transferase (GART), which is involved in catalytic steps of the de novo

purine synthesis pathway. Thus, the overproduction of these genes may have
positive effects on development by providing successful clearance of free

radicals or producing energy via enhanced nucleotide synthesis. GART may have
beneficial properties, but increased expression of GART can be harmful due to

the increase in purines which can cause gout and in general an increase in uric

acid levels. In contrast the overexpression of amyloid precursor protein (APP),
which is mutated in some forms of AD which promotes the self aggregation and
accumulation of beta-amyloid, and the increased levels of β-site APP-cleaving 2

enzyme (BACE2) (Fig. 1) likely play negative roles in the proper development of
DS individuals, especially in the brain.

1.2 Chromosome 21

HSA21 is the smallest of the human chromosomes consisting of the short (p) arm

in which the sequence remains unknown and the long (q) arm that was discovered

to contain about 225 genes, although many of their functions and specific role in DS
remain unclear [10]. The best defined region of HSA21 is known as the “Down

syndrome critical region” (DSCR) (Fig. 1). The DSCR segment contains about 33

genes that are conserved in various species, these genes are known to be associated
with DS and are suggested to lead to the craniofacial abnormalities, short stature,
3

joint hyperlaxity, hypotonia and mental retardation that Individuals with down
syndrome display [11]. DSCR1 is known as Regulator of Calcineurin (RCAN1),

which is highly expressed in brain, heart and skeletal muscle [12]. Also located on

HSA21 is the gene, Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase-

1A (DYRK1A) that acts to phosphorylate several transcription factors and is known
to be involved in neuronal differentiation in the hippocampus [13]. RCAN1 and

DYRK1A are both highly studied proteins since they play significant roles in normal
cellular function, but there are a host of other genes found on HSA21 that are

postulated to also play a large role in the phenotypic pathology of DS such as Ets-2,

Cu/Zn SOD1, and APP.

4

Figure 1: Chromosome 21, Location of the Most Studied DS Genes. The genes located
on the p arm of HSA21 are not as well characterized compared to that of the longer
q arm. APP, SOD1, DSCR and BACE2 are commonly investigated for their
contribution to the neuropathology of DS. [14].
1.2,1 RCAN1
RCAN1 has four splice variants of which RCAN1-1 is the most abundant,

producing a protein that is 197 amino acids long and is found primarily and

abundantly in the brains of fetuses and adults [15]. RCAN1 co-localizes with
synaptophysin suggesting that it is expressed on synaptic vesicles. The

overexpression of RCAN1 has been shown to cause aggresomes similar to those
observed in DS and AD brains and reduces synaptophysin expression in neural
5

processes [16]. In DS, abnormal vesicle trafficking precedes the neuronal deposition
of Aβ in the brain. Also, there is a decreased recycling of late endosomes as well as
an increase of enlarged early endosomes. The negative effect of RCAN1 on

synaptophysin implies that overexpression of RCAN1 in DS adversely affects

exocytosis, endocytosis and vesicle trafficking, important functions for the normal
development and plasticity of a brain.

When neurons overexpress RCAN1 they show a marked increase of

mitochondria that exhibit smaller morphologies, an increase of reactive oxygen

species (ROS), and decreased ATP production [17]. The increase of ROS in these

neurons could play a part in the hippocampal and cortical loss of neurons observed
in DS. Poor mitochondrial dynamics and cellular oxidative stress are involved in

lethal cellular pathways and will be addressed in detail later in this thesis. Certainly,

it is possible that RCAN1 effects such as reducing ATP and increasing production of

ROS contributes to the decreased numbers of viable cells in the brains of individuals

with DS.

1.2,2 DYRK1A
DYRK1A overexpression has many deleterious effects in DS (Fig. 2). It has been

shown to hyperphosphorylate important proteins in the brain, as well as inhibit
neuronal precursor proliferation. When the serine-theonine protein kinase,
DYRK1A, is overexpressed both APP and Tau show increased levels of

phosphorylation [18]. Tau is a microtubule stabilizing protein that is disrupted
6

from microtubules when hyperphosphorylated. After Tau becomes

hyperphosphorylated it promotes self-assembly of axonal tangles. Neuronal tangles
and hyperphosphorylated Tau are prominent hallmarks of AD. DYRK1A also leads
to AD like pathology by phosphorylating APP on the intracellular domain at

threonine 668 as well as some β-amyloid fragments [19, 20]. Phosphorylation in
cells is a tightly regulated process often acting as a molecular switch. Because

DYRK1A is up-regulated in DS and phosphorylates many proteins such as Tau, APP

and Aβ, essential neuronal processes including differentiation, APP processing, and
Tau phosphorylation are negatively impacted (Fig. 2) [20].

Figure 2: Summary of the role of DYRK1A Overexpression in DS. Schematic of the
neurological consequences due to the overexpression of DYRK1A. The
hyperphosphorylation of NFAT, APP, Tau, and α-synuclein are due to the increased
production of DYRK1A. Increased DYRK1A promotes its own overexpression by
7

increasing the amount of β-amyloid production via phosphorylation of APP. Figure
reproduced from., [20].

DYRK1A can also function as a regulator of basic molecular metabolism, which is

achieved by DYRK1A phosphorylating eukaryotic protein synthesis initiation factor
2B epsilon (eIF2Bε) and glycogen synthase [21]. The effects that DYRK1A has on

eIF2Bε and glycogen synthase give rise to the theory that this gene can regulate the

cellular cycle. Whether or not DYRK1A modulates the cellular cycle is debatable, but

this gene is widely involved in many essential cellular processes.
1.2,3 Ets-2

Ets-2, is a gene also located on HSA21 and has been suggested to be involved in

the pathogenesis of DS. Ets-2 is a transcription factor involved in many cellular

processes such as differentiation, maturation, and activation of certain signaling
cascades [22]. The role that ets-2 plays in DS is thought to be one of a harmful
protein which, when its expression is increased, predisposes cells to undergo

apoptosis via a p53-dependent pathway [23]. The increased expression of ets-2
leads to apoptosis by activating p53, which promotes the upregulation of

mitochondrial pro-apoptotic factors Bax and apoptotic activating factor-1 (Apaf-1).

The activation of p53 inhibits the transcription of pro-survival proteins including Bcell lymphoma-2 (Bcl-2) and Inhibitors of Apoptosis (IAPs) [24]. In DS ets-2

overexpression is associated with bax activation, intracellular Aβ accumulation, and
hyperphosphorylation of tau, suggesting that ets-2 overexpression may contribute
8

to the neuronal loss and degradation that Individuals with down syndrome
experience.

The antioxidant enzyme SOD1 is also located on the q arm of HSA21 and has

been found to be overexpressed by ~50% in DS individuals. The function of SOD1 is
to catalyze the dismutation of superoxide anions to hydrogen peroxide. The

increased expression of this enzyme may lead to an increase in reactive oxygen

species in DS [25]. Mis-folded or mutated SOD1 has been studied as the cause of the
disease amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig’s disease.
SOD1 has also been studied in relation to the gene dosage theory in DS. SOD1

overexpression is implicated in increased lipid peroxidation and cellular oxidative

damage [26]. Cellular respiration and metabolism are necessary for life, but the byproducts of these processes produce ROS. These ROS are also known as free

•
•
radicals and include superoxide (O2 -), hydroxyl radical (OH ), hydrogen peroxide

(H2O2) and peroxynitrite (NO3-). Hydrogen peroxide and peroxynitrite can be

converted to highly reactive molecules through the Fenton reaction which converts
•

•

H2O2 to OH and NO3- to OH as well [14]. These highly reactive molecules are then

able to react and damage nuclear and mitochondrial DNA often leading to apoptosis.
SOD1 works as a first line cellular antioxidant defense by catalyzing the dismutation

•
of O2 - to molecular oxygen (O2) and hydrogen peroxide (Fig. 3). Hydrogen peroxide

is then converted to water by catalase (CAT) and glutathione peroxidase (GPX) [27].
9

Figure 3: Mechanism of SOD1 Breaking Down Superoxide. The expression of 1.5
times its normal level in Individuals with down syndrome causes an imbalance in
the ratio of SOD1 to that of CAT and GPX resulting in an accumulation of H2O2.
Figure Reproduced from., [28].

Oxidative stress and mtDNA damage can cause death in all cells, but neurons are

more susceptible to ROS. Fetal loss of unnecessary neurons is common, but the loss
of functional neurons because of ROS is detrimental to a developed brain due to the
fact that neurons are post mitotic. Elevated levels of SOD1 in DS brains most likely
plays a significant negative role because of the contribution to the increased

production of hydrogen peroxide leading to an increase of the Fenton reaction
producing greater levels of OH

•

.
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1.3 Amyloid Precursor Protein

Figure 4: Ribbon Structure of the Amyloid Precursor Protein. (www.pdb.com)
APP, often referred to as the Alzheimer’s gene is most frequently cited as a

potential cause of the global dementia and neuronal loss seen in individuals with DS
(Fig. 4). Also located on HSA21, this gene is repeatedly found upregulated in

individuals with DS as well as the accumulation of its cleavage product, β-amyloid,
which forms neuronal plaques and has been found as early as 8 years of age in DS

patients [29]. APP has several isoforms ranging from 365 to 770 amino acid

residues [30]. APP is cleaved by three proteins termed α-, β- and γ-secretases (Fig.

5). The cleavage of APP by α- and β-secretase releases large soluble proteins titled
APPsα and APPsβ respectively [31]. These two soluble proteins are then cleaved
11

again by γ-secretase. Cleavage of APPsα by γ-secretase produces a 3 kDa product

entitled p3, whereas the cleavage of APPsβ by the same γ-secretase releases the well
known Aβ fragment. Along with the production of either p3 or Aβ from the cleavage
of APPsα and APPsβ, γ-secretase also produces from both precursor proteins, the
APP intracellular domain (AICD). AICD and p3 are essentially innocuous when it
comes to plaques and dementia; however the cleavage product of APPsβ, Aβ, is

responsible for the formation of plaques and ultimately neuronal loss. There are

two isoforms derived from the cleavage of APPsβ, the shorter being Aβ(1-40 amino
acids) and the longer more neurotoxic form, Aβ(1-42 amino acids). There are two

initial cleavage products of APP, previously listed, but the factors that promote the

generation of one product over the other are unclear. One such factor appears to be
the gene β-amyloid cleaving enzyme (BACE2) which is also located on HSA21.

Although it is not typically overexpressed at the 1.5x level observed for APP it is still
found to be somewhat up-regulated in DS. The increased activity of this enzyme

promotes the formation of the APPsβ fragment, thus increasing of the release of the
neurotoxic Aβ fragment [32].

12

Figure 5: Pathway of APP Processing by α-, β- and γ-secretases. APP is cleaved by
α or β secretases, these fragments are then processed by γ-secretases to produce
AICD and p3 or Aβ.

DS and AD are linked in many ways, but the most notable being that by the age of

40, virtually all individuals with DS exhibit the neuropathology of AD [33]. APP is a

ubiquitously expressed transmembrane type I protein, found in many tissues, but is

concentrated in the synapses of neurons [34]. The cellular location of APP gives rise
to the theory that APP may play a part in the formation and regulation of synapses
and neural plasticity [35]. Although APP itself has certain roles in the brain, the

neuronal pathology of AD is more closely associated with its cleavage product, Aβ.
APP is overexpressed in Individuals with down syndrome and this inevitably

leads to an increased amount of soluble amyloid-β in the brain. The increase of Aβ
13

fragments promotes self-aggregation leading to the formation of plaques. Aβ fibrils

are cytotoxic to neurons due to Aβ’s ability to trigger cells to generate oxygen free

radicals [36]. Experimental data suggests that monomers, oligomers, and fibrils of
Aβ negatively impact proliferation and differentiation of neural progenitor cells
(NPCs). If Aβ suppresses cellular proliferation and differentiation, then the

observed overexpression of APP in DS is a likely contributor to the neuronal loss

and early onset AD that DS patients occasionally develop. Aβ also induces oxidative
stress by activating microglia, increasing neuronal calcium influx (Ca2+), and

inducing apoptosis [37]. An increase in intracellular calcium has been implicated in
activating the intrinsic apoptosis pathway.

Normal brain development involves the generation of neurons and extensions of

axons, neuronal pruning then follows this phase so that appropriate connections are
strengthened and maintained. Widespread loss of neuronal connections underlies
the neurophysiology of DS and AD in DS. When neurons are destined for

degeneration they are often targeted by extrinsic signals or intrinsic factors that

promote apoptosis. DR6, also known as tumor necrosis factor receptor superfamily,
member 21 (TNFRSF21), can regulate neuronal death and axonal pruning [38]. If

neurotrophic factors are insufficient, DR6 will trigger neuronal cell body and axon

degeneration by activating a Bax and caspase-3-dependant apoptosis cascade [39].
Nikolaev 2009 reported that the extracellular fragment of APP acts as a ligand for

DR6 indicating that APP itself is sufficient to trigger neuronal cell death and axonal
pruning [38].

14

Overexpressed APP has indirect negative effects on mitochondria as a result of

the increased ROS and increased intracellular calcium levels, but APP also has a
direct impact on the dynamics of mitochondria. APP carries a mitochondria-

targeting signal sequence in its N-terminal domain, which causes APP to insert itself
into mitochondrial import channels [40]. APP has been found in the mitochondria

of cortical neurons of AD transgenic mice and when overexpressed in cultured cells,
APP is once again found within mitochondria [41]. When APP accumulates in the
mitochondria, these organelles then become susceptible to swelling as well as
leaking ROS into the cytosol an in turn causes intrinsic apoptosis [42].

APP overexpression has negative impacts on normal neuronal and cellular

processes. These are achieved through the production of ROS, disruption of
mitochondrial dynamics and accumulation of toxic plaques. Because APP is

overexpressed in Individuals with Down syndrome it is likely that APP plays a

significant role in the neuronal loss observed in the hippocampus and cortex of DS

individuals.

1.4 Mitochondrial Oxidative Stress and Lipid Peroxidation
Some of the genes located on HSA21, such as ets-2, SOD1, RCAN1 and APP

have been implicated in increased production of ROS leading to cellular and

mitochondrial oxidative stress in DS individuals. Mitochondrial DNA (mtDNA) is 10
times more vulnerable to oxidative damage in vivo compared to that of nuclear
DNA; the increased production of ROS that these proteins produce is especially
15

harmful when overexpressed in DS [14]. Although mitochondria are very

susceptible to ROS, because of cellular respiration they are also large producers of
the very same ROS. Due to their high affinity to oxidize cellular components, ROS

often cause DNA double stranded breaks (DSBs). Current theories suggest that mild
DNA stress will slowly induce impairment, often seen in ageing, whereas acute
oxidative stress triggers the mechanisms involved in cellular death [43].

The damage to mtDNA that is induced by increased levels of ROS leads to

mutations in mtDNA-encoded proteins [44]. MtDNA is more susceptible to ROS

because there are no histones to protect the DNA, and because mitochondrial are

the largest producers of ROS in a cell [40]. The errors in the mtDNA cause defects in
the mitochondrial complexes that are involved in the electron transport chain. If
one of these complexes is mis-folded or contains mutations then its ability to

successfully shuttle highly reactive electrons between other complexes in the

mitochondrial inner membrane become inhibited, leading to an increase of ROS.
Along with oxidizing mtDNA, ROS can also cause damage to the lipid

membranes of cells. Because lipids are critical to the structure and function of cells,
any disruption to their function can lead to cell death. The double bonds found in
polyunsaturated fatty acids (PUFAs) which help form the membranes of cells are

ready targets for free radical attack [45]. The hydrogen atoms in PUFAs are most

susceptible to peroxidation by free radicals. Once this hydrogen is oxidized a chain
reaction is set into motion by the creation of a new radical molecule. The newly

created molecule is then able to remove another hydrogen from another PUFA [46].
16

When a large portion of lipid molecules are disrupted the function of ion channels,
and other membrane proteins are also disrupted affecting the entire lipid
membrane and homeostasis of the cell.

Cells do contain molecules that inhibit the destructive nature of ROS, the

most abundant of which is glutathione (GSH), which is the tri-peptide, γ-glutamyl-

cysteinyl-glycine. Anti-oxidant GSH, in the company of GPX reacts readily with ROS
•

generating the glutathiyl radical (GS ) which is much less oxidizing than the original
•

molecule [47]. This GS radical rapidly reacts with another GSH molecule to form

oxidized glutathione (GSSG). The donation of hydrogen by GSH maintains the

important balance of ROS and oxidized molecules. Mitochondria are unable to
synthesize GSH, therefore mitochondrial GSH originates in the cytosol and is

transported into mitochondria [48]. When mitochondrial GSH is depleted, these
organelles become extremely susceptible to oxidative stress. The danger of

mitochondrial oxidative stress lies downstream of the mitochondria itself. It is the
pro-apoptotic molecules such as cytochrome c that are contained within the
mitochondria that cause widespread cellular damage.

In the erythrocytes of AD individuals, GSH levels have been found to be

decreased, along with a corresponding downregulation of glutamate-cysteine ligase
(GCL) and glutathione synthase (GS), the two enzymes involved in de novo GSH

synthesis [49]. Reports have also found that in individuals with down syndrome
17

levels of GSH are also markedly reduced [50]. With the reduction in this critical

anti-oxidant that both AD and DS patients exhibit, it is only a matter of time until

certain cells are overcome by normal mitochondrial respiration and production of

ROS. Normal aging is thought to arise from cells that are overcome by ROS; it seems

that cells from these DS and AD individuals succumb to this much faster or that

these afflicted cells are less prepared for ROS increases due to the reduction of GSH.
1.5 Intrinsic Apoptosis Pathway
There are two apoptotic pathways the extrinsic and intrinsic. The extrinsic

apoptosis pathway is activated when the Fas ligand binds to its extracellular

receptor which activates caspase-8 eventually leading to apoptosis. The intrinsic

apoptotic pathway is initiated through specific activation of pro-apoptotic molecules
that are normally sequestered within the mitochondria of healthy cells. The signals
that typically activate this pathway result from oxidative stress, detachment from
the extracellular matrix, a defective cell cycle, hypoxia, or a loss of cell survival

factors [51]. Mitochondria are key players in the intrinsic apoptosis pathway and
activation of this pathway is caused by the permeabilization of the outer

mitochondrial membrane (Fig. 6). When this occurs pro-apoptotic molecules such

as cytochrome c are released into the cytosol where they activate cystiene-

dependent, aspartate-specific proteases (caspases). Caspases are zymogens that
upon cleavage are activated and able to cleave essential cellular proteins
propagating the steps involved in apoptosis.
18

When permeable mitochondria release cytochrome c the apoptosome is

formed, a large oligomer complex composed of cytochrome c, Apaf-1, and caspase-9.
Cytochrome c binds to the C–terminal region of Apaf-1, allowing Apaf-1 to

oligomerize and become a scaffold for caspase-9 [52]. Caspase-3 is activated by the
apoptosome through cleavage by caspase-9 and is known as the executioner

caspase. Activated caspase-3 then moves on to cleave key proteins in the cell causes
the cellular and biochemical events of apoptosis [51].

Mitochondrial swelling and enhanced outer membrane permeability

promotes apoptosis through an alternative route that also activates the intrinsic

apoptotic pathway, titled the mitochondrial permeability transition pore (mtPTP).
This pore is thought to be composed of the voltage-dependent anion channel

(VDAC), members of the Bax-Bcl-2 protein family, cyclophilin D, and the adenine

nucleotide translocator (ANT) [53]. In earlier sections, it was noted that oxidative
stress and increases in intracellular Ca2+ have been implicated in neurological

diseases. Normal respiring mitochondria take up calcium ions; however, if

excessive calcium ions are incorporated into the mitochondria then mitochondrial
matrix swelling occurs and the mtPTP is susceptible to being activated. Upon

activation of the mtPTP, VDAC turns into a non-selective pore where it allows ions

and small molecules (~1500 Da) to enter the matrix. Due to the large surface area
in the matrix of mitochondria, swelling of this compartment causes rupture of the

organelle allowing cytochrome c to escape mitochondria and activate the intrinsic
apoptotic cascade [54].
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Bax is a pro-apoptotic cytosolic protein that is a member of the B-cell

lymphoma protein family . When activated, bax localizes to the outer mitochondrial
membrane and oligomerizes to form pores. Bax is normally a monomeric protein
and is unable to form channels in mitochondria but when activated, usually by

truncated BID (tBID) a Bcl-2 Homology-3-only (BH3-only) pro-apoptotic protein, is

able to oligomerize and form channels. Oligomeric bax forms a pore that is between
2.7-5.4 nm wide which is sufficient to allow the passage of ~3 nm cytochrome c

though the pore and into the cytosol [55, 56]. These bax channels are also voltage

independent and are fairly cation selective, thus small molecules including calcium

are able to enter the mitochondrial inner membrane space and cause swelling. The
channels formed by bax can be inhibited by anti-apoptotic members of the Bcl-2
family. Bcl-2 itself is able to prevent bax activated apoptosis as well as
mitochondrial oxidative stress.

Bak is another pro-apoptotic member of the Bcl-2 family. Unlike bax, bak

resides on the outer membrane of mitochondria. Bak is an effector molecule for

mitochondrial outer membrane permeabilizaiton (MOMP) [57]. Bak is activated

when tBID migrates to the mitochondrial membrane and recruits bax to the same
location. When bax is activated it once again inserts itself into the membrane

forming homo (bax/bax) or hetero (bax/bak) dimers forming the MOMP complex
[58]. The oligomerization of Bax and bak forms the mitochondrial apoptosisinduced channel (MAC) which allows cytochrome c to be released from
mitochondria (Fig. 6) [59].
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Figure 6: Intrinsic Apoptosis Cascade. tBid activates bax and bak increasing
mitochondrial outer membrane permeabilization. ROS promote the activation of
these two molecules, but bax/bak effects can be attenuated by Bcl-2. Released
cytochrome c activates APAF-1 caspase-9 caspase-3 apoptosis.
1.6 Hypothesis and Rationale
Previous studies have shown that APP causes an increase in intracellular

calcium as well as disruption of normal mitochondrial dynamics. We hypothesized
that due to the overexpression of APP, cells will undergo apoptosis through an
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intrinsic apoptotic cascade induced by increased intracellular levels of calcium that

initiate the process of triggering the mtPTP.

APP is overexpressed in DS individuals, therefore we assessed whether APP’s

effects on mitochondrial oxidative stress and activation of pro-apoptotic factors

could be prevented by antioxidants or anti-apoptotic molecules. If this is the case,

then our findings would suggest that individuals with DS and AD might benefit from
such strategies aimed at mitigating the neurotoxic effects of APP.
1.7 Summary of Major Findings
Using a transient transfection strategy of APP in combination with

fluorescence imaging and western blot analysis we detected a significant elevation

in apoptosis, and mitochondrial oxidative stress due to the overexpression of APP in
CHO cells. Demonstration of the release of cytochrome c from mitochondria

solidified our hypothesis that APP was causing activation of the intrinsic apoptotic
cascade.

Along with the detection of apoptosis through the use of western blotting and

fluorescence imaging we were able to demonstrate a marked increase in ROS and
mitochondrial oxidative stress through the use of glutathione assays and a
mitochondrial permeability transition pore assay.

Finally, we showed that antioxidant (exogenous glutathione) and anti-

apoptotic (caspase inhibitors or Bcl-2 overexpression) were strategies that
provided significant protection from APP-induced toxicity.
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Collectively, these novel findings indicate that APP overexpression likely

plays a deleterious role in DS via the induction of mitochondrial oxidative stress that
is sufficient to cause activation of the intrinsic apoptosis cascade. Future studies
aim to replicate the findings in this study in a more relevant neuronal system.
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2.1 Reagents

CHAPTER TWO: MATERIALS AND METHODS

4,6-diamidino-2-phenylindole (DAPI), and Hoechst Dye number 33258 were

purchased from Sigma (St. Louis, MO). Glutathione monoethyl ester (GSH) was

purchased from Calbiochem (San Diego, CA). The pan-caspase family inhibitor Boc-

D (OMe)-FMK was from Alexis Biochemicals (Plymouth Meeting, PA). Caspase 3

antibody was purchased from Promega (Madison, WI). Horseradish peroxidaseconjugated secondary antibodies and reagents for chemiluminescence detection
were purchased from Amersham Biosciences (Piscataway, NJ). DsRed-2 was

obtained from Invitrogen (Carlsbad, CA). Image-iT live mitochondrial transition

pore assay kit was purchased from Invitrogen (Carlsbad, CA). Cytochrome C anti-

body was purchased from Biolegen (San Diego, CA). APP antibody was purchased

from Abcam (Cambridge, MA). COX-IV antibody was purchased from Cell Signaling
(Boston, MA). Bax-6A7 antibody was purchased from Alexsis Biochemicals

(Plymouth Meeting, PA). Cyclosporin A was purchased from Alexis Biochemicals

(Plymouth Meeting, PA). Maxi-prep plasmid kits were purchased from (Valencia,

CA). Kanamycin and Ampicillin were purchased from Sigma Aldrich (St. Louis, MO).
F-12 Ham CHO cells media was purchased from Sigma Aldrich (St. Louis, MO)

Lipofectamine-2000 was purchased from Invitrogen (Carlsbad, CA). Opti-Mem was

purchased from Invitrogen (Carlsbad, CA). JM109 competent E. Coli was purchased

from Promega (Madison, WI). Staurosporine was purchased from Sigma Aldrich (St.
Louis, MO). Mitochondrial/Cyotosolic fractionation kit was purchased from Bio
24

Vision (Mountain View, CA). Glutathione assay kit was purchased from Oxford
Biomedical (Oxford, MI).
2.2 CHO Cell Culture
K1-CHO cells were a generous gift from Dr. David Patterson. Cells were

plated on 35-mm diameter plastic dishes in F12-Ham’s media containing 10% fetal
bovine serum, 2mM L-glutamine and (100 U/ml/100 µg/ml)

penicillin/streptomycin. Cells were cultured overnight at 37°C in 10% CO2. The
following day cells were prepared for transfection or treatment, at which point
cultures were 60-80% confluent.
2.3 CHO Cell Transfection

Plasmids encoding DsRed-2 or DsRed-APPwt proteins were transfected at a

concentration of 5ug of DNA. Co-transfection with Bcl-2 plasmid utilized 10µg of

DNA. 50µl of Opti-mem minus the pre-calculated volume of plasmid was incubated

at room temperature for 10 minutes. Correspondingly, 45µl of Opti-mem and 5µl of
lipofectamine-2000 reagent were incubated at room temperature for 10 minutes.

The mixture of lipofectamine-2000 and Opti-mem were then mixed together and
incubated for 20 minutes at room temperature. During the 20 min incubation

period the 6-well dishes of CHO were and washed twice in 37°C Opti-mem. Final
volume of Opti-mem for the transfection was 1ml. The 100µl of DNA-

Lipofectamine-2000 and Opti-mem were then added to each well of the 6-well plate.
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After which the cells were incubated for 6 h at 37ºC, 10%CO2, and finally the Optimem was replaced with 1ml of F-12 HAM media as described above.
2.4 Bacterial Transformation of DsRed-2

DsRed-2 was obtained from Clontech at a concentration of 500 ng/µl, the

plasmid was diluted to a final working concentration of 50ng/µl. 100µl of JM109

competent Escherichia coli cells were placed in a pre-chilled falcon tube on ice. 1µl

of .7M β-Mercaptoethanol was added to the cells and swirled every 2 minutes for 10
minutes. Next, 1µl of the diluted DsRed-2 plasmid was added to the E. coli cells and
incubated on ice for 30 minutes. After the 30 min incubation cells were heat
shocked for 45 s and incubated on ice for 2 m. Next, 900µl of LB broth with

Ampicillin at a concentration of 100µg/ml was added to the tube. The tube

containing the cells and broth was shaken at 200 RPMs at 37º C for 1 h. Next 50µl of
cells were plated on an LB agar plate containing 100µg/ml Ampicillin and spread
using a sterile glass pipette. The agar plate was then incubated at 37ºC degrees
overnight.

2.5 Bacterial Transformation of DsRed-APPwt
DsRed-APPwt was the kind gift of Dr. Xiongwei Zhu at a concentration of 50

ng/µl. DsRed-APPwt was transformed as stated above.
2.6 Bacterial Transformation of Bcl-2

Bcl-2 plasmid was transformed as stated above.
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2.7 DsRed-2, DsRed-APPwt and Bcl-2 Plasmid Preparation
After plasmid transformation, individual colonies were selected from the

agar plates using a 10µl pipette and incubated in 5ml of LB broth with Ampicilin

100µg/ml (DsRed-2, Bcl-2) or Kanamycin (DsRed-APPwt) 40µg/ml for 6-8 h at 37ºC
shaking at 200RPMs. After the 6 h were complete, starter cultures were diluted

1:250 and incubated over night. Plasmids were prepared using a Qiagen endo-free

Maxi-prep kit. Cultures were pelleted and collected in a 250ml bottle and spun at

4ºC at 10,000 x g for 30 minutes. The supernatant was removed and the cells were

re-suspended in pre-chilled 10ml buffer P1 (50 mM Tris HCl pH 8.0, 10mM EDTA, 10
µg/ml RNASE A). 10ml buffer P2 (200mM NaOH, 1% SDS, 1 M NaOH, 10% SDS,

H2O) was added to mixture and incubate at room temperature for 5 minutes. Next,

pre-chilled buffer P3 (3.0 M KOAc pH 5.5) was added to the mixture and poured into
the barrel of the cartridge. The mixture incubated at room temperature for 10

minutes at which point a plunger was inserted into the barrel and lowered with
moderate force transferring approximately 25ml of supernatant to a 50ml

polycarbonate tube. 2.5ml of buffer ER (endotoxin removal) was added and

inverted 4-6 times and incubated on ice for 30 minutes. As the mixture incubated
on ice, a separate Qiagen-500 filter tip was equilibrated with 10ml of buffer QBT
(750 mM NaCl, 50 mM MOPS, pH 7.0, 15% isoproponol and .15% Triton X-100).

Next the mixture was poured into the Qiagen-500 filter tip and filtered by gravity.

The filter was washed two times with 30ml of Qiagen buffer QC (1.0 M NaCl, 50 mM

MOPS pH 7.0, 15% isopropanol) by gravity flow. Plasmid DNA was eluted into 50ml
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polycarbonate tube by filtering adding 15ml of buffer QN (1.6 M NaCl, 50 nM MOPS
pH 7.0, 15% isopropanol) to the filter tip. DNA was precipitated with 10.5ml of

100% isopropanol to eluted DNA and centrifuged at 4ºC for 30 minutes at 15,000 x
g. The approximately 30ml supernatant was decanted and the pellet was

resuspended in 5ml endotoxin-free 70% ethanol, and centrifuged for 10 minutes at
15,000 x g at 4ºC . The 5ml supernatant was decanted and the pellet was

resuspended in 200µl of buffer TE (10 mM Tris-Cl pH 8.0, 1 mM EDTA) and allowed
to air dry. Upon retrieval of plasmid/buffer mixture 1.5 µl of sample was analyzed

using Thermo Scientific NanoDrop 2000 to determine DNA concentrations.

2.8 Bcl-2 Bacterial Transformation
Bcl-2 bacterial transformation was prepared using the exact protocol of the

DsRed-2 plasmid. See previous DsRed-2 protocol.
2.9 Treatments

Immediately following transfection cells were supplemented with specific

treatments and incubated for ~24 h.
Treatment

Concentration

Glutathione- endogenous antioxidant

2mM

Boc- pan caspase inhibitor

Staurosporine- Bax activator

50µM

500nM
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Cyclosporine A- Immunosuppressant

1µM, 10µM

Bcl-2- anti-apoptotic protein

10µg of plasmid

drug

Table I: Treatments that were used for CHO Cell Experiments.
2.10 Immunocytochemistry/Fluorescent Imaging
24 h post-transfection and treatments, cells were washed once in 1x PBS and

then fixed with 1ml of 4% Paraformaldehyde for 45 min at room temperature. Cells
were then permeabilized and blocked with 5% BSA in 0.2% Triton X-100/1xPBSat

room temperature for 1 h. Primary antibodies were diluted as in table II in 2% BSA
in 0.2% Triton X-100/1xPBS, and 1ml was added to each well and incubated
overnight at 4ºC. The following day cells were washed 5x with 1X PBS, and

secondary antibody at a dilution of 1:250 in 2% BSA in 0.2% Triton X-100/1X-PBS

was prepared and 1ml was added per well for 1 h incubation at room temperature.
Next, cells were washed 5x in 1X PBS, and placed in 1ml of an anti-quench solution
prepared from 1X PBS and 1-5 mg of p-phenylenediamine. For DAPI staining only,
cells were incubated for 1 h at room temperature in 2% blocking solution as

previously stated. Fluorescent images were captured using a 50x objective on a
Zeiss Axiovert microscope.
Antibody or Stain

4’,6-diamidino-2-phenylindole (DAPI)Chomatin stain

Concentration
1:1000
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Hoechst- Chromatin stain

1:1000

6A7-Anti-Active Bax pAb

1:200

Anti-Active Caspase-3 pAb
FITC-Anti Rabbit
FITC-Anti Mouse

1:1000
1:250
1:250

Table II: Antibodies And Stains Utilized for Experiments.
2.11 Subcellular Fractionation
A Mitochondrial/Cytosolic fractionation kit was obtained from BioVision, Inc.

Buffers for each fractionation were prepared as follows: 1ml of cytosolic buffer was
diluted in 4ml of ddH2O, 10µl protease inhibitors, and 5µl of dithiothreitol (DTT)

were added. 2µl of protease inhibitors and 1µl of DTT were added to 1ml of the 1X
mitochondrial buffer. Cells were washed 1x with ice-cold 1XPBS. The 1XPBS was

aspirated and 200µl of cytosolic extraction buffer added per well and incubated on
ice for 20 min. After which cells were scraped, harvested, and transferred into a

microcentrifuge tube. Lysates were then Dounce homogenized ~40 times. Heavy

membrane lipids were fractioned by spinning at 4ºC for 10 minutes at 720 relative

centrifugal force (RCF). Supernatant was transferred to a clean microcentrifuge

tube and mitochondria were fractionated by centrifugation at 10,000 RCF for 30

min. Next, the supernantant was transferred to new tube. The mitochondrial pellet

was resuspended in 100-150µl of mitochondrial extraction buffer.
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2.12 Cell Lysis and Immunoblotting
Post transfection and treatment cells were washed 1 time with 1X ice cold

PBS; pH 7.4 and were incubated for 20 minutes on ice with 200µl of cytosolic
extraction buffer. Samples were scraped from the wells and combined into a

microcentrifuge tube. Protein concentration was determined using a protein assay
kit; (BCA, Pierce Chemical Co., Rockford, IL) and 60µg of protein were

electrophoresed through polyacrylamide gels, and resolved proteins were
transferred to polyvinylidene difluoride (PVDF) membranes (Amersham

Biosciences, Piscataway, NJ). Immunoblotting was performed by blocking PVDF

membranes in 1X PBS; pH 7.4 with 0.1% Tween 20 (PBS-T) containing 1% BSA and
0.001% sodium azide for 1 h at room temperature. The primary antibody was
diluted in blocking solution according to manufactures recommendations and

incubated with membrane for 1 h. Membranes were then washed 5x over 30 min

with PBS-T. Next, membranes were incubated for 1 h with horseradish peroxidaseconjugated secondary antibodies diluted in PBS-T, following, membranes were
washed 5x over 30 min with PBS-T. This was followed by detection of
immunoreactive proteins with enhanced chemiluminescence.
2.13 Glutathione Assay (Oxford Biomedical Research, GT-35)
An Oxford Biomedical Research glutathione kit was used, but solutions were

scaled to 96-well plate reader dish. After mitochondrial/cytosolic fractionation was
performed as described above. All kit buffers were made per manufacturer’s
31

instructions. 30µl of pre-made standards were added to the 96-well plate. 30µl of

pre-made reductase with DTNB and 30µl reductase for 10 min was added to each

well including sample wells. During which samples were added to the 96-well plate
at a 1:5 dilution. Next, 30µl of NADPH was added to standards, and 30µl DTNB was

added to samples. Absorbance was read at 412nm in a Bioteck Spectrophotometer.
2.14 Image-IT Live PTP Assay (Invitrogen Kit, I35103)

24 h post transfection, CHO cells were washed 1x with Hank’s balanced

buffered salt solution (pH 7.4), and cells were placed in 997µl of Hank’s buffer.
1.0mM calcein AM, 1.0mM Hoechst 33342, and 1.0M Cobalt (II) chloride

hexahydrate were added at 1µl each per well of cells. Cells were incubated at 37ºC
incubator at 10% CO2 and incubated for 15 minutes. Upon completion of the 15-

minute incubation cells are washed 1x with Hank’s balanced buffered salt solution
(pH 7.4) and live imaged under fluorescence microscopy.
2.15 Statistical Analysis and Quantification of Data
Recorded values of apoptosis, caspase-3 activation, DNA fragmentation and,

mitochondria permeability transition pore opening were quantified from 30 images
per treatment. Graphical data represent the mean ±SEM for the respective

experiments. Only transfected cells were counted in each field disregarding

untransfected cells. Values are shown as a percentage of total transfected cells.

Most experiments are a representative of an n=3 value. Statistical analysis of these
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experiments was performed using GraphPad Prism, each respective experiment was
analyzed for significance with a 1-way analysis of variance (ANOVA) and a post hocTukey’s test. Accepted significance had a p value <0.05.

Glutathione assays raw data was analyzed by exporting the kinetic data to

Microsoft Excel. The kinetic data was then averaged to fit a standard curve, only R2

values greater than .950 were accepted. Slope of curves were used as kinetic rate of
reduced GSH concentration and were normalized to previously determined sample

protein concentrations. These values are all represented as a percentage of control
(DsRed-2).
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CHAPTER THREE: RESULTS

3.1 Overexprssion of Amyloid Precursor Protein Induces Apoptosis in CHO Cells
To explore the effects of APP on apoptosis in CHO cells we used 60-80%

confluent cells and transfected them with an APP plasmid for 6 h. The cells were

then incubated for an additional 24 h before imaging. Transfection efficiency was
approximately 30-50% as assessed by DsRed fluorescence. We also transfected

cells with an empty DsRed-2 vector as a control to ensure that the plasmid and or

transfection procedure were not causing the cells to undergo apoptosis. Cells were
fixed and stained with DAPI to image nuclear morphology. Interestingly, CHO cells

that overexpressed APP showed distinct fragmented or condensed nuclei indicative
of apoptosis whereas, CHO cells that only expressed the empty vector had normal

nuclear morphology (Fig.7 & 8).
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Figure 7: Overexpression of APP induces nuclear condensation and fragmentation in
CHO cells. Panel A: DsRed-2 (red) transfected cells with nuclei DAPI (blue) stained.
The nuclei are round and intact indicating a healthy cell. Panel B: APP (red)
transfected cell with nuclei DAPI (blue) stained. The nuclei are fragmented lacking
order, indicating apoptosis. Panel C: APP (red) transfected cell with nuclei DAPI
(blue) stained. The nucleus is condensed indicating apoptosis.
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Figure 8: Overexpression of APP induces apoptosis in CHO cells. Panel A: Image of
desaturated DAPI (grey) stained APP (red) transfected CHO cells. Arrows denote
transfected apoptotic cells. Panel B: Image of DAPI desaturated (grey) stained
DsRed-2 (red) transfected CHO cells. Arrows denote transfected healthy cells. Panel
C: Image of DAPI (blue) APP (red) transfected CHO cells. Arrows denote apoptotic
transfected cells. Panel D: Image of DAPI (blue) DsRed-2 (red) transfected cells.
Arrows denote healthy transfected CHO cells.
3.2 Overexpression of APP Activates Caspase-3

Because apoptosis is mediated by caspases we next wanted to determine

whether or not APP overexpression causes apoptosis though a caspase-dependent
mechanism in CHO cells. Cells were once again transfected for 6 h and incubated

for an additional 24 h. Following incubation, cells were fixed and stained with DAPI
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to show nuclear morphology and then co-stained with a rabbit polyclonal antibody
against the active form of caspase-3. Using an anti-rabbit antibody conjugated to a
FITC tag, the cells were imaged using a Zeiss Axiovert 200 2 EPI Fluoresence

inverted microscope. Compared to DsRed-2, APP overexpressing CHO cells revealed
a marked increase in caspase-3 activation, indicating that APP causes activation of
an apoptotic pathway (Figure 9).

Figure 9: APP overexpression induces caspase-3 activation. Left Panel: transfected
APP (red) cells, nuclei DAPI (blue) stained and active caspase-3 with a FITC (green).
Right Panel: DsRed-2 (red) transfected CHO cells, stained as in previous panel.
3.3 Boc, Glutathione & Bcl-2 Prevent APP Induced Apoptosis
Upon finding that CHO cell death due to overexpression of APP was through a

caspase-3 mechanism, we next analyzed the nuclear morphology and chromatin
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fragmentation of cells that were overexpressing APP either alone or in combination

with antioxidant or anti-apoptotic agents. APP overexpressing cells were co treated
with a pan caspase inhibitor (Boc), the anti oxidant glutathione, or the pro-survival

protein Bcl-2. To supplement CHO cells with Bcl-2 we co-expressed a Bcl-2 plasmid,

and an APP plasmid at twice the transfection concentration of the APP plasmid. Due
to the fact that the Bcl-2 plasmid produces no fluorescent protein we doubled the

transfection concentration of Bcl-2 over that of APP to ensure that the majority of
cells expressing APP were also co-expressing Bcl-2. After 24 h post transfection,

cells were fixed and stained with DAPI and imaged for nuclear morphology. APP

once again caused a large proportion of the cells to exhibit nuclear fragmentation

and/or condensation. Interestingly, CHO cells that were supplemented with either
Boc, GSH or Bcl-2 showed very low levels of apoptosis as assessed by nuclear

fragmentation (Fig. 10). The findings that Boc and Bcl-2 were each able to protect

against APP-induced apoptosis led us to believe that APP caused cell death through
an intrinsic apoptosis pathway. Earlier we observed that APP activated Caspase-3,
the executioner caspase, and that the only cells consistently undergoing apoptosis

were ones expressing APP. The protection that was observed when cells were

treated with GSH was mechanistically distinct from that of Boc and Bcl-2. Notably,

the intrinsic anti-oxidant properties of GSH protect against oxidative stress and
perhaps in APP treated cells, specifically mitochondrial oxidative stress. In

conclusion Bcl-2, GSH and Boc all maintained healthy nuclei and prevented nuclear
condensation in response to APP overexpression (Fig. 10).
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Figure 10: Bcl-2, GSH, and Boc protect from APP induced apoptosis. Panel A:
transfected APP (red) cells, nuclei DAPI (blue) stained. Panel B: APP (red)
transfected CHO cells with Bcl-2 plasmid (no-color), nuclei DAPI (blue) stained.
Panel C: APP (red) transfect cells treated with Boc, nuclei DAPI (blue) stained.
Panel D: APP (red) transfected cells treated with GSH, nuclei DAPI (blue) stained.
Arrow indicated apoptotic cells determined by nuclear morphology.
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3.4 Quantification of APP Induced Apoptosis
Transfected CHO cells were identified by Ds-Red fluorescence and the

averages of apoptotic cells were determined from each treatment population. When
cells were transfected with DsRed-2 the population remained relatively healthy

with only ~7% apoptosis. CHO cells overexpressing APP were significantly induced
to undergo apoptosis at a rate of roughly 55%. The death induced by APP

overexpression was reduced significantly when cells were co-treated with Boc, GSH
or Bcl-2 (Fig. 11). Apoptosis was quantified initially as transfected cells whose

nuclei showed fragmentation and condensation, common hallmarks of apoptosis
.
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Figure 11: Quantification of APP induced apoptosis and protective effects of Boc, GSH,
and Bcl-2. Thirty images per treatment were captured, corresponding transfected
apoptotic cells were quantified. The total apoptotic cells per treatment were
divided by the total number of transfected cells counted and converted into a
percent. APP significantly increased apoptosis compared to control DsRed-2 where
as Boc, GSH and Bcl-2 were able to reduce apoptosis approximately to control levels.
*p<0.05 APP vs. APP+Bcl-2, **p<0.01 APP vs. APP+Boc, ***p<0.001
APP vs DsRed-2 & APP+GSH. p=0.0006, n=3
3.5 APP Overexpression Induces Nuclear Fragmentation

As a sub-study of APPs effects on nuclear morphology, we specifically examined

nuclear fragmentation in CHO cells. We were surprised to find that values for DNA
fragmentation were very similar to that for total apoptosis of the cells. DsRed-2
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cells had very low levels of DNA fragmentation averaging ~6.5%. APP

overexpressing cells showed significantly increased nuclear fragmentation

compared to that of control DsRed-2 cells up to ~56%. Similar to total apoptosis,
Boc, GSH and Bcl-2 each significantly reduced nuclear fragmentation due to APP
overexpression (Fig.12). These findings suggest a marked activation of caspase
activated DNases (CADs) in cells overexpressing APP.

Figure 12: Quantification of APP Induced DNA Fragmentation. Thirty images per
treatment were captured, corresponding transfected cells with fragmented DNA
were counted. The total fragmented cells per treatment were divided by the total
number of transfected cells quantified and converted into a percent. APP
significantly increased apoptosis compared to control (DsRed-2) where as Boc, GSH
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and Bcl-2 were able to reduce caspase-3 activation to control levels. ***p<0.001
DsRed-2, APP+Boc, APP+GSH, APP+Bcl-2 vs. APP. p<0.0001, n=3.
3.6 APP Induced Caspase-3 Activation is Attenuated by Boc, Glutathione & Bcl-2
Apoptosis and caspase-3 activation were clearly induced by the

overexpression of APP in CHO cells. Because Boc, GSH and Bcl-2 all showed

protective effects against APP-induced apoptosis, the next logical step was to

determine whether or not these same compounds were able to prevent caspase-3

activation. This experiment was performed similarly to previous experiments. CHO
cells were transfected for 6 h with either DsRed-2 or DsRed-APP. Upon completion
of the transfection, GSH or Boc was added to the cells; alternatively Bcl-2 plasmid

was once again co-transfected with the original APP plasmid. Cells were incubated
for 24 h and then fixed and stained with DAPI and an anti-active caspase-3

described previously. Boc, GSH and Bcl-2 were each able to considerably reduce the
appearance of active caspase-3 (Fig. 13).
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Figure 13: Immunocytochemistry of Boc, GSH & Bcl-2, Caspase-3 Activation. Panel A:
transfected APP (red) cells, nuclei DAPI (blue) stained and active caspase-3 with a
FITC (green). Panel B: APP (red) transfected CHO cells with Bcl-2 plasmid (not
shown or stained), nuclei DAPI (blue) stained and active caspase-3 with a FITC
(green). Panel C: APP (red) transfect cells treated with Boc, nuclei DAPI (blue)
stained, and active caspase-3 with a FITC (green). Panel D: APP (red) transfected
cells treated with GSH, nuclei DAPI (blue) stained, and active caspase-3 with a FITC
(green).
3.7 Quantification of Caspase-3 Activation

When caspase-3 activation was analyzed quantitatively, the results were

quite similar to that of apoptosis quantification. Once again all transfected cells

were counted and examined for overlap of DsRed fluorescence with green (FITC)

fluorescence indicating active caspase-3. DsRed-2 transfected CHO cells revealed

low levels of caspase-3 activation, (~7%). Cells that were overexpressing APP had
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significant levels of activated caspase-3 at a rate of approximately 56%. The

activation of caspase-3 induced by APP overexpression was reduced significantly
when cells were treated with either Boc, GSH, or Bcl-2 (Fig. 14).

Figure 14: Quantification of APP Stimulated Caspase-3 Activation. APP significantly
increases caspase-3 activation compared to control where as Boc, GSH and Bcl-2
were able to reduce caspase-3 activation to approximately control levels. **p<0.01
APP vs. APP+GSH, ***p<0.001 APP vs DsRed-2, APP+Boc & Bcl-2. p<0.0001, n=3.
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3.8 Western Blot Analysis of APP Oxerexpression
To ensure that APP overexpression in transfected CHO cells was not affected

by Boc, GSH or Bcl-2 co-transfection, we performed western blots on whole cell

lysates at 24 h post-transfection. We observed no detectable APP protein in DsRed-

2 transfected cells. In contrast, cells that were transfected with APP either alone or
in combination with Boc, GSH, or Bcl-2 all showed detectable and approximately
equal levels of human APP protein (Fig. 15). Fascinatingly, the Bcl-2 transfected
cells did not display the APP doublet that was observed in either APP or those

treated with Boc or GSH control cells. It is postulated that Bcl-2 may be interacting
with APP in a way that is preventing certain processing events; nonetheless, the
details of this possible interaction will be studied in more detail at a later date.

Figure 15: Western Blot analysis of Human APP Overexpression. Human APP was
detected from 95 kD to 110 kD. The upper bands are processed APP while the lower
kD bands are the unprocessed APP proteins. Tubulin is shown as a loading control
and detected at ~50 kD.
3.9 APP Overexpression Causes Depletion of Mitochondrial and Cytosolic Glutathione
When APP overexpressing CHO cells were supplemented with GSH

immediately post-transfection they displayed a marked decrease in apoptosis and
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caspase-3 activation. We theorized that oxidative stress may be involved in the

cellular death that these CHO cells were experiencing in response to APP. Because
GSH is the most abundant endogenous anti-oxidant in cell, measurement of this

peptide is an indirect indicator of cellular oxidative stress. CHO cell transfections
were performed exactly as previous described. After 24 h incubation, cells were

harvested, lysed and centrifuged to separate mitochondrial fractions from that of
cytosolic cellular components. The mitochondrial portion of the lysates were resuspended in an appropriate buffer and, both the cytosolic and mitochondrial

fractions were analyzed for GSH in a 96-well kinetic assay and read using a plate

spectrophotometer at 412nm. The readings were then normalized to protein levels

and analyzed against a standard curve of GSH.

Using DsRed-2 as our control, all other values were taken as a percentage of

this control level. The experiments revealed that APP significantly depleted both

the cytosolic and mitochondrial pools of GSH (Fig. 16). Cells treated with Boc were
not protected from the mitochondrial loss of GSH, where as Bcl-2 and GSH

supplementation showed considerable protection of the mitochondrial GSH pool
(Fig. 16A).

Glutathione levels in the cytosolic fractions were dramatically reduced when

cells were overexpresing APP alone. This loss of GSH in the cytosol was blunted
when cells were treated with either Boc, Bcl-2 or GSH (Fig 16B).

Boc most likely was unable to prevent GSH loss in the mitochondria because

Boc prevents caspase activation which occurs down stream of mitochondrial
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oxidative stress. Activated caspases cleave γ-glutamylcystiene ligase (GCL), the rate
limiting enzyme in the de novo synthesis of GSH [60]. Boc protected the cytosolic

portion of GSH because in theory the caspases in the cytosol were prevented from
being activated by boc, thus inhibiting their negative impact on GCL activity and
cytosolic GSH levels. Bcl-2 overexpression has been shown to elevate GSH
concentrations and prevent GSH depletion during stress [60-62].

48

Figure 16: Quantification of Glutathione in the Mitochondria and Cytosol.
DsRed-2 was used as a control. All other treatment values were compared to
control values. APP and APP/Boc treated cells were unable to protect against the
depletion of GSH in the mitochondria. APP/GSH and APP/Bcl-2 treated cells
attenuated mitochondrial glutathione depletion. APP treated cells depleted GSH in
the cytosolic portion where as APP/Boc, APP/GSH and APP/Bcl-2 all protected
against APP induced glutathione depletion in the cytosol. n=2.
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3.10 Overexpression of APP Activates the Mitochondrial Permeability Transition Pore
APP caused substantial oxidative stress in CHO cells as evidenced by their

reduced GSH levels, indicating that these cells had increased levels of ROS. When

levels of ROS are increased, especially in the mitochondria, the mtPTP is susceptible
to being activated. To determine whether or not APP induced the activation of the
mtPTP we transfected CHO cells similarly to previous experiment and then used a
cobalt/calcein assay to measure mtPTP opening. After 24 h incubation live cells

were washed once with Hank’s balanced salt solution (pH 7.4) and then Hoechst

was added for nuclear staining along with cobalt chloride (CoCl2) and calcein AM.

Cobalt chloride is a molecule that localizes to the matrix of mitochondria, whereas
calcein AM localizes to the cytosol. Cells were incubated in this media for 15
minutes and then washed and prepared for live cell fluorescence imaging.
If the mtPTP is activated then CoCl2 is released from the matrix of

mitochondria into the cytosol allowing it to react with and quench the fluorescence
signal of calcein. This simple experiment was used as an indicator of mtPTP

activation. Cells that were transfected with DsRed-2 maintained high levels of

calcein staining, whereas cells transfected with APP displayed diminished levels of
calcein fluorescence (Fig. 17). The results of the APP expressing cells losing their
calcein staining indicates the activation of the mtPTP. When APP overexpressing

cells were supplemented with Boc, once again the mtPTP was activated. In contrast,
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glutathione supplementation was able to prevent the activation of mtPTP in this
experiment.

Boc works down-stream of the mtPTP by inhibiting caspase activation. On

the other hand glutathione is an antioxidant which was able to protect against the

activation of the mtPTP by reducing the levels of ROS within the mitochondria. APP
most likely caused activation of the mtPTP due to the depletion of mitochondrial

GSH and the consequent increase in mitochondrial oxidative stress, which sensitizes
the mtPTP to elevations in intracellular Ca2+ which are also caused by the
overexpression of APP.
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Figure 17: Immunocytochemistry of Mitochondrial Permeability Transition Pore
Activation. Red fluorescence indicates mito-tracker red staining. Panel A: DsRed-2
transfected cells maintained high levels of calcein AM staining indicating the mtPTP
was not activated. Panel B: APP transfected cells lost most calcein AM staining
indicating activation of mtPTP. Panel C: Boc was unable to protect against mtPTP
activation in APP transfected cells. Panel D: APP cells treated with GSH maintained
high levels of calcein AM, displaying a protection against mtPTP activation.
3.11 Quantification of Mitochondrial PTP Activation

When the data from the mtPTP activation experiment was analyzed, DsRed-2

mtPTP activation was relatively low around 30%. When DsRed-2 transfected cells
were treated with ionomycin, a positive control (images not shown), mtPTP
activation increased to ~70%. Ionomycin is a calcium ionophore and when

administered to healthy cells it floods them with calcium thus causing mitochondria
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to swell activating the mtPTP. Ionomycin-mtPTP activation was almost

indistinguishable from that observed with APP alone or APP supplemented with Boc

(Fig 18.). However GSH and Bcl-2 reduced mtPTP activation in the presence of APP
down to the level observed in mock transfected cells.

Figure 18: Quantification of Mitochondrial Permeability Transition Pore Activation.
Ionomycin, APP and APP/Boc treated cells all significantly activated the mtPTP.
APP cells treated with GSH or expressing Bcl-2 had similar to control levels of
mtPTP activation. **p<0.01 DsRed-2, APP+GSH & APP+Bcl-2 vs. DsRed-2 +
Ionomycin, APP & APP+Boc. p<0.0003, n=3.
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3.12 APP Overexpression Causes Mitochondrial Release of Cytochrome C
The release of cytochrome c is one of the initiating steps involved in the

intrinsic apoptosis pathway. To ensure that the mechanism of death we were

detecting involved cytochrome c release we performed a western blot analysis on

transfected cells. In this experiment we separated the cells into mitochondrial and
cytosolic fractions. Because cytochrome c is normally found within mitochondria

we could be sure that cytochrome c was being released from mitochondria if it was
present in the cytosolic fractions of our cells. When we examined cells transfected
with DsRed-2 there was no detectable cytochrome c in the cytosol; these results

were anticipated due to the low levels of apoptosis and caspase activation that we

observed in previous studies. When we transfected CHO cells with APP there were
detectable levels of cytochrome c in the cytosolic and the mitochondrial portions of
our lysates (Fig. 19). This indicates that APP overexpression causes the release of
cytochrome c from the mitochondria into the cytosol. Although the levels of
detected cytochrome c in the cytosol were not as pronounced as that in the

mitochondrial fractionation, one must take into account that transfection efficiency
is not 100%, so the cytochrome c observed in the cytosolic portion is most likely a

true representation of the relatively small population of APP transfected CHO cells

that are actually releasing cytochrome c. Interestingly, when APP transfected cells
were supplemented with GSH the release of cytochrome c into the cytosol was

reduced, similar to the results previously observed in that GSH reduces oxidative
stress and apoptosis due to APP overexpression.
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Figure 19: Western Blot Analysis of Mitochondrial/Cytosolic Fractionation for
Cytochrome C. 60µg of each sample were loaded in a 15% gel and ran overnight for
full separation of proteins. Cytochrome c bands were detected at 15 kD, COX IV
detected at 16 kD. The COX IV western blot is shown as a loading control and to
ensure pure fractions of mitochondria and cytosol.
3.13 APP Causes Apoptosis Through a Bax-Independent Mechanism
Given the fact the bax is inherently involved in the intrinsic apoptosis

pathway we wanted to determine whether or not bax was implicated in the death
pathway that APP overexpressing CHO cells were experiencing. To study this

question we transfected CHO cells with APP as previously described. After the 24 h
incubation, cells were washed, fixed and stained with DAPI and a 6A7-monoclonal

mouse antibody against the active conformation of bax. Concurrently, as a control

untransfected CHO cells were treated with the known bax activator, staurosporine.

Cells were prepared for fluorescence imaging and to our surprise, the APP

overexpressing cells displayed very little-to-no active bax staining compared to that
of staurosporine treated cells which fluoresced brightly indicating widespread

active bax staining (Fig 20.). Although the APP transfected cells did not indicate bax
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activation the same cells were still experiencing apoptosis which was visualized by
the nuclear fragmentation and condensation. These results indicate that APP

overexpression is sufficient to cause apoptosis, but it is achieved through a bax
independent mechanism.

Figure 20: Immunocytochemistry of Bax Activation. Panel A: CHO cells transfected
with APP (red) and counterstained with DAPI (blue) and 6A7-anti-bax with FITC
(green). Panel B: CHO cells treated with 500 nM Staurosporine, stained with DAPI
(blue) and 6A7-anti-bax with FITC (green).
3.14 Cyclosporin A May Prevent APP Induced Apoptosis

The effects of APP on the mtPTP were quite dramatic in CHO cells. It is

thought that inhibiting the mtPTP might be beneficial at reducing apoptosis. In fact
we did observe a reduction of mtPTP activation and apoptosis with the

supplementation of GSH, likely as a result of its antioxidant effects which would be
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expected to de-sensitize the mtPTP to increases in intracellular calcium. The
immunosuppressive drug cyclosporin A (CSA) has been shown to prevent

depolarization of mitochondria and inhibit the mtPTP via binding to cyclophilin D,
an integral component of the mtPTP [54]. In this preliminary experiment we

transfected CHO cells for 6 h with APP and then treated the transfected cells with
either 1µM or 10µM CSA to determine if direct inhibition of the mtPTP would be
sufficient to protect against APP induced apoptosis. After imaging these cells for
apoptosis and caspase-3 activation it became evident that our first experiment

showed promising results in that cyclosporin A at the higher concentration was able
to protect against apoptosis and caspase activation in APP overexpressing cells (Fig.
21).
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Figure 21: Quantification of Apoptosis in Cyclosporin A Treated Cells. Images of
apoptotic cells were observed for apoptosis, APP caused ~48% apoptosis. APP+CSA
1µM had ~39% apoptosis & 10µM CSA experienced 23% apoptosis. N=1.
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CHAPTER FOUR: DISCUSSION
The two leading hypotheses’ of DS suggest that either the overexpression of a

single gene is responsible for the characteristics of DS or that all the genes on the
chromosome are no longer in homeostasis produce cognitive disturbances and

neuronal death characterized in DS. Perhaps the overexpression of certain genes
produces a deleterious effect downstream of the protein and gene product itself.

Overexpression of genes such as APP have been shown to significantly increase the
expression levels of Aβ, and it has been reported that increased serum levels of Aβ
lead to aggregation and plaques formed by Aβ, in the Ts65Dn mouse reduction of
amyloid beta serum levels has been shown to rescue memory and learning [63].

Although APP is the precursor protein for Aβ, it is the downstream effects of the
protein that induces many of the cognitive hallmarks of AD and AD in DS.

The observations made in this study illustrate that overexpression of APP

causes mitochondrial oxidative stress by depleting GSH, which consequently

activates the intrinsic apoptosis cascade. These toxic effects of APP are significantly
attenuated by compounds that target either the intrinsic apoptosis pathway (Bcl-2,
Boc & Cyclosporin A) or oxidative stress (GSH). It has been reported that APP
overexpression is able to induce increased intracellular levels of Ca2+, axonal

pruning and general apoptosis. We have made the novel observation that as a result
of causing mitochondrial oxidative stress, APP also induces the opening of mtPTP,
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triggers release of cytochrome c from mitochondria, and activates the executioner
protease, caspase-3 leading to apoptosis.

Our results show that APP causes apoptosis, this is consistent with previous

studies showing that overexpression of APP triggers death in cells. Although the
aforementioned studies suggested that APP acts primarily through an extrinsic

pathway involving TNF receptors, we discovered that CHO cells die in response to
APP through an intrinsic apoptotic pathway [38]. Caspase-3 is the executioner
caspase and upon activation of this protease, the cell is committed to die by

apoptosis. In APP overexpressing CHO cells caspase-3 activation was significantly
increased indicating that the cells were overwhelmed by this protease and were

induced to undergo cell suicide. Other studies have reported that the secretion of

APP or Aβ is able to cause apoptosis via a paracrine mechanism in surrounding cells
[64]. The previous report also suggested that the apoptosis induced by APP

occurred through an extrinsic pathway. Conversely the death that CHO cells

experience in response to APP occurs through an intrinsic mechanism. CHO cells

that were transfected with APP were the only cells undergoing apoptosis, while cells

that were not transfected remained healthy and viable. Thus, we found no evidence
of a paracrine release mechanisms for APP toxicity in CHO cells.

Recent studies suggest that intracellular GSH depletion may result in

mitochondrial malfunction [65]. The mitochondrial and cytosolic levels of GSH
were significantly reduced in CHO cells overexpressing APP indicating that the

functions of mitochondria may have been impaired. The loss of this essential
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antioxidant due to the increased expression of APP indicates that these cells are

succumbing to oxidative stress. Further study of the activation of the mitochondrial
permeability transition pore demonstrated key involvement of mitochondrial

oxidative stress is involved in activating this death pathway. The mtPTP is activated
when components of the channel become oxidized (eg., ANT), Thus if there is a loss
of antioxidants in the mitochondria and APP increases oxidative stress, then

susceptible mitochondria open the mtPTP allowing the intake of small molecules
and water leading to outer membrane rupture and eventual cell death.

The result that APP failed to induce bax activation in our system was

surprising given that bax is often implicated in the intrinsic apoptosis cascade.

These findings lead us to believe that there may be another protein that is being

activated in the intrinsic apoptosis cascade. Rises in intracellular Ca2+ have been
reported to cause endoplasmic reticulum (ER) stress, which in turn results in a

release of ER Ca2+ stores [66]. The Ca2+ released from the ER is then able to enter

the mitochondria and once again activate the mtPTP and trigger intrinsic apoptosis.

Observing the effects of APP overexpresison on ER dynamics is of great importance
due to the presence of an ER signaling sequence that APP carries [42]. The

overexpression of APP may allow for this protein to insert itself into the membrane
of the ER causing stress and general disruption of protein production causing

degradation of the ER network and an eventual release of Ca2+ stores. The finding

that bax is not involved in cell death due to APP overexpression also suggests that

caspase-2 or an alternative caspase may be involved in the release of cytochrome c.
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Caspase-2 is a direct activator of the intrinsic apoptosis pathway, and is also able to

directly cause cytochrome c release [67]. Due to the negative results of active bax in
APP expressing cells, further studies of alternative caspases and intrinsic apoptosis
mediators such as Bid and Puma need to be performed.

Using the immunosuppressive drug cyclosporine A we were able to

significantly prevent APP induced apoptosis. Cyclosporin A is known to prevent

cyclophilin D from becoming a member of the mtPTP essentially inactivating the

pore itself. The results that were observed when APP overexpressing cells were

treated with cyclosporin A indicate that activation of the mtPTP is directly involved
in the death pathway that our cells were experiencing. GSH and Bcl-2 were able to
protect against the depletion of mitochondrial levels of glutathione as well as

prevent caspase activation and the opening of the mtPTP. Through our mtPTP

experiments we showed that inhibition of the pore mediates whether or not cells
overexpressing APP undergo apoptosis unless blocked downstream by an
alternative mechanism (eg. Boc).

During western blot analysis we noticed that CHO cells co-expressing APP

and Bcl-2 produced a singlet band of protein of APP where as other treatments and
APP alone repeatedly produced a doublet band of protein for APP. We hypothesize
that Bcl-2 and a lower molecular weight peptide of APP are reacting thus the signal

of the doublet was lost. Current studies support this hypothesis, Yang et al, found
that overexpressed APP, Bcl-2 and certain heat shock proteins form a complex in
mitochondria of stressed cells. Although this is a hypothesis, there is also
62

considerable data that suggest Bcl-2 can protect against amyloid-beta toxicity by

lowering Ca2+ influx and prevent mitochondrial oxidative stress [68]. The

mechanisms of how Bcl-2 is able to achieve these cellular protective effects are not

well known, but further investigation could lead to discoveries that would explain
the unexpected results that our APP western blots produced when co-expressing

Bcl-2. In order to study the possible interactions of Bcl-2 and APP in our cell system

we could perform a transfection and immunoprecipitation to determine whether or

not APP or Bcl-2 are able to be pulled down together on a western blot. APP carries
an ER localization signal, but it has also been shown to carry a mitochondrial

localization signal which allows it to insert into the membrane of mitochondrial.

The mitochondrial localization signal could be imperative to the Bcl-2 interaction
due to Bcl-2’s key interactions with mitochondria and mitochondria import
machinery.

Developing fetal brains are more susceptible to oxidative stress, due to the

lack of a fully developed neural network that promotes the growth and retention of
newly formed fragile neurons. The future directions of our experiments aim to

replicate these results in primary neuronal cultures, and perhaps test these results
in vivo on the widely used Ts65Dn DS mouse model. If these results can be

replicated in neurons in vitro and in vivo in a mouse model of DS; mitochondrial

oxidative stress, mtPTP activation, and the intrinsic apoptosis cascade may prove to

be relevant therapeutic targets for the AD-like pathology observed in DS individuals.
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APP and Aβ have proven to be toxic to cells in certain instances, in our study

it was not determined that the toxicity CHO cells overexpressing APP were

succumbing to was from APP itself or its cleavage product Aβ. In the future we

would like to expand our study to measure Aβ peptide in DsRed-2 control cells and

compare the levels to that of CHO cells overexpressing APP using an ELISA. Perhaps
there is a certain threshold of APP production that causes a cell to undergo

apoptosis or promotes a cell to produce more Aβ. Understanding the measureable

levels of proteins produced either APP or Aβ would be beneficial to comprehend the
range of toxic proteins that must be reduced to protect a cell from certain death.

The way that these levels could be determined is by performing a titration of our
plasmid and measuring apoptosis and protein levels in the media by an ELISA.
Performing titrations would be essential to ensure that the levels of APP are
comparable to that of in vivo levels.

The effects that DS and AD in DS produce are what mentally debilitate these

individuals. Because DS occurs maternally in meiosis I, the ability to inhibit the

triplication of HSA21 is beyond the reach of modern science. It is the treatment and
reduction of the overexpression of the genes on HSA21 that is a more suitable way
to treat individuals with DS and perhaps protect against the widespread neuronal
loss that individuals with DS develop. Our results help to progress the field by

identifying certain protective strategies to mitigate the toxicity induced by APP

overexpression. These strategies may provide new therapeutic approaches to stem
the progression of neuronal loss in DS and in AD in DS.
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